ESIDRIX
LOE ApproachingNDAORALTABLET
Approved
Feb 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ESIDRIX is a legacy oral small-molecule diuretic approved in 1959 as an NDA by Novartis. The drug's specific indication, mechanism of action, and pharmacologic class are not documented in available data. The product is positioned in a mature market with approaching loss of exclusivity.
LOE Approaching
Product faces imminent generic competition with moderate competitive pressure (30%), indicating a contracting brand team and focus on cost management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No active job listings are currently linked to ESIDRIX, and the product's LOE-approaching status suggests minimal hiring. Career opportunities are limited to maintenance roles focused on maximizing remaining revenue and managing transition to generics.
Brand ManagerField Sales Representative
Worked on ESIDRIX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.